益生菌补充剂对精神分裂症患者代谢综合征成分的影响：一项随机、双盲、安慰剂对照试验。

Effects of synbiotic supplementation on the components of metabolic syndrome in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial.

机构信息

Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.

Research Center for Prevention of Cardiovascular Disease, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran.

出版信息

BMC Psychiatry. 2024 Oct 9;24(1):669. doi: 10.1186/s12888-024-06061-y.

DOI:10.1186/s12888-024-06061-y

PMID:39385189

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11462647/

Abstract

BACKGROUND

Antipsychotic drugs may have adverse effects on the components of metabolic syndrome. Previous studies have shown that changes in the intestinal microbiome are associated with metabolic disturbances in patients with schizophrenia. The objective of this study was to determine the effects of synbiotics on the components of metabolic syndrome as primary outcomes in patients with schizophrenia. Secondary outcomes were HbA1c, insulin resistance, LDL-c, and anthropometric measurements.

METHODS

In this double-blind, placebo-controlled trial, seventy patients with schizophrenia receiving antipsychotic drugs who had at least two criteria of metabolic syndrome were randomly divided into two groups to receive either two capsules of a synbiotic supplement or a placebo daily for 8 weeks. Anthropometric indices and biochemical parameters were measured at baseline and after the intervention.

RESULTS

Fifty-five patients completed the study. The synbiotic supplement significantly decreased waist circumference and HbA1C compared to placebo (-2.66 ± 4.20 vs. 3.03 ± 4.50 and - 0.26 ± 0.54 vs. 0.20 ± 0.75, respectively). Although BMI did not change significantly in the synbiotic + antipsychotic group, it increased in the placebo + antipsychotic group (-0.37 ± 1.00 vs. 0.61 ± 1.09 P < 0.5). LDL-c and triglyceride (TG) levels decreased significantly in the synbiotic + antipsychotic group, but the change was not significantly different from that of the placebo + antipsychotic group. FBS, HDL-c, systolic and diastolic blood pressure, insulin resistance, and total cholesterol were not significantly different between the two groups after intervention.

CONCLUSION

Synbiotic supplement may decrease waist circumference, HbA1c, LDL and TG and prevent BMI increase in patients receiving antipsychotic drugs.

TRIAL REGISTRATION

Iranian Registry of Clinical Trials (IRCT Number: IRCT20090901002394N45), Date: 26-12-2019.

摘要

背景

抗精神病药物可能会对代谢综合征的各项指标产生不良影响。先前的研究表明，肠道微生物组的变化与精神分裂症患者的代谢紊乱有关。本研究旨在确定益生菌-益生元对接受抗精神病药物治疗的精神分裂症患者代谢综合征各项指标的影响，将其作为主要结果。次要结果是糖化血红蛋白（HbA1c）、胰岛素抵抗、低密度脂蛋白胆固醇（LDL-c）和人体测量学指标。

方法

在这项双盲、安慰剂对照试验中，70 名正在接受抗精神病药物治疗且至少有两项代谢综合征标准的精神分裂症患者被随机分为两组，每天分别服用两种益生菌-益生元补充剂胶囊或安慰剂，持续 8 周。在基线和干预后测量人体测量学指标和生化参数。

结果

55 名患者完成了研究。与安慰剂相比，益生菌-益生元补充剂显著降低了腰围和 HbA1C（-2.66±4.20 与 3.03±4.50 和-0.26±0.54 与 0.20±0.75）。虽然益生菌-抗精神病药物组的 BMI 没有显著变化，但安慰剂-抗精神病药物组的 BMI 增加（-0.37±1.00 与 0.61±1.09，P<0.05）。益生菌-抗精神病药物组的 LDL-c 和三酰甘油（TG）水平显著降低，但与安慰剂-抗精神病药物组相比，变化无统计学意义。干预后两组间空腹血糖（FBS）、高密度脂蛋白胆固醇（HDL-c）、收缩压和舒张压、胰岛素抵抗和总胆固醇无显著差异。